Eric Walker added Moving from push to pull | Laboratory News to 2019-10 Public Health England report on antibiotic resistance in England, Antibiotic resistance and pharmaceutical business models and 2019-07 AMR Centre to license Shionogi COT-143 antibody

Eric Walker added Shionogi announces out-licensing agreement with AMR Centre on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa | More News | News Channels to 2019-07 AMR Centre to license Shionogi COT-143 antibody

Eric Walker added Alderley Park to run Japanese AMR therapy | Laboratory News to 2019-07 AMR Centre to license Shionogi COT-143 antibody

Eric Walker added Shionogi announces out-licensing agreement with AMR Centre on COT-143, a humanized monoclonal antibody targeting the PcrV protein of Pseudomonas aeruginosa to 2019-07 AMR Centre to license Shionogi COT-143 antibody

Eric Walker added Pharma companies AMR Centre and Shionogi in landmark deal to develop 'superbug' treatment - Business Live to 2019-07 AMR Centre to license Shionogi COT-143 antibody

Eric Walker added AMR Centre, Shionogi team up for superbug therapy - PharmaTimes to 2019-07 AMR Centre to license Shionogi COT-143 antibody

Eric Walker added a number of topics and a number of links to Antibiotic resistance and the development of new drugs, and added Antibiotic resistance and the development of new drugs to Antibiotic resistance (ABR), Antimicrobial resistance and the development of new antimicrobials and New and investigational drugs

Eric Walker added a number of links to 2019-07 AMR Centre to license Shionogi COT-143 antibody, and added 2019-07 AMR Centre to license Shionogi COT-143 antibody to β-lactam resistant Pseudomonas aeruginosa and Antibiotic resistance and the development of new drugs

Eric Walker added 2019-07 Case Western Reserve University study on Ceftazidime-Avibactam and multidrug-resistant Pseudomonas aeruginosa, 2019-07 Deraya University study on Pseudomonas aeruginosa and 2019-07 AMR Centre to license Shionogi COT-143 antibody and a number of links to β-lactam-resistant Pseudomonas aeruginosa, and added β-lactam-resistant Pseudomonas aeruginosa to Drug-resistant Pseudomonas aeruginosa